Cite

HARVARD Citation

    Uprety, D. et al. (2018). The Role of Osimertinib in Treatment Naïve Epidermal Growth Factor Receptor–Mutated Stage IIIB or IV Non–Small-Cell Lung Cancer Patients. Clinical medicine insights. Oncology. p. . [Online]. 
  
Back to record